WVE
Wave Life Sciences Ltd.
$5.70
-0.52%
$1.1B
No data for this timeframe.
Vol
Market Cap$1.1B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (95%)
Insider Activity3B / 4S
Insider Net $$52.1M
Reddit Sentiment53° Neutral
SEC Reports6
Press Releases2
Recent Activity
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: WVE-006 (Phase 2)
Trial: A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Partic
May 18, 2026
Press
Wave Life Sciences reported strong updated Phase 1b/2a data for WVE-006 in AATD, showing restoration of wild-type M-AAT
Impact 7/10
Apr 28, 2026
SEC
Wave Life Sciences reported Q1 2026 EPS of -$0.13, beating consensus estimates of -$0.34 by 61.8%, and revenue of $38.2M
8-K — Impact 7/10
Apr 28, 2026
SEC
Wave Life Sciences reported Q1 2026 revenue of $38.2M (vs consensus $7.9M) and EPS of -$0.13 (vs consensus -$0.31), repr
PRESS-RELEASE — Impact 7/10
Apr 22, 2026
SEC
Wave Life Sciences (WVE) announced it will report first-quarter 2026 financial results on April 28, 2026, via a live web
PRESS-RELEASE — Impact 4/10
Mar 30, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. bought 971,091 shares
Director @ $6.50 ($6.3M)
Mar 27, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. bought 2,495,623 shares
Director @ $6.43 ($16.0M)
Mar 26, 2026
Press
Wave Life Sciences released positive Phase 1 data for WVE-007, an investigational obesity treatment, showing significant
Impact 8/10
Price Targets
$21.94
+279.5% upside
Strong Buy
Current $5.78
Low $12.00
Median $18.50
High $43.00
16 analysts
$12.00
$43.00
Analyst Ratings
6Strong Buy
13Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 20, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 4, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Apr 30, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Apr 29, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.30 | $-0.33 — $-0.25 | 3% YoY | 11 |
| Next Q | $-0.31 | $-0.37 — $-0.27 | 2% YoY | 11 |
| Current FY | $-0.88 | $-1.33 — $1.64 | 28% YoY | 12 |
| Next FY | $-1.11 ▲ +17.3% | $-1.78 — $-0.03 | -27% YoY | 12 |
Latest Reports
BULLISH
Press
7/10
Wave Life Sciences reported strong updated Phase 1b/2a data for WVE-006 in AATD, showing restoration of wild-type M-AAT
May 18, 2026
BULLISH
8-K
7/10
Wave Life Sciences reported Q1 2026 EPS of -$0.13, beating consensus estimates of -$0.34 by 61.8%, and revenue of $38.2M
Apr 28, 2026
BULLISH
PRESS-RELEASE
7/10
Wave Life Sciences reported Q1 2026 revenue of $38.2M (vs consensus $7.9M) and EPS of -$0.13 (vs consensus -$0.31), repr
Apr 28, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 30, 2026 | RA CAPITAL | BUY | $6.3M |
| Mar 27, 2026 | RA CAPITAL | BUY | $16.0M |
| Mar 26, 2026 | RA CAPITAL | BUY | $30.0M |
| Mar 23, 2026 | TAKANASHI KEN | C | $0.00 |
| Mar 23, 2026 | TAKANASHI KEN | C | $0.00 |
Reddit Sentiment
53°▲
Neutral
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
6 unique insiders with 7 transactions. Net insider value: $52.1M ($52.4M bought, $258.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 971,091 | $6.50 | $6.3M |
| Mar 27, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 2,495,623 | $6.43 | $16.0M |
| Mar 26, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 4,954,558 | $6.06 | $30.0M |
| Mar 23, 2026 | TAKANASHI KEN | Director | C | 3,901,348 | $0.00 | $0.00 |
| Mar 23, 2026 | TAKANASHI KEN | Director | C | 3,901,348 | $0.00 | $0.00 |
| Feb 26, 2026 | Francis Chris | See Remarks | M | 17,900 | $3.87 | $69.3K |
| Feb 26, 2026 | Francis Chris | See Remarks | M | 17,900 | $0.00 | $0.00 |
| Feb 9, 2026 | Moran Kyle | Chief Financial Officer | SELL | 3,588 | $13.45 | $48.3K |
| Feb 9, 2026 | BOLNO PAUL | President and CEO | SELL | 10,480 | $13.45 | $141.0K |
| Feb 9, 2026 | Francis Chris | See Remarks | SELL | 1,883 | $13.45 | $25.3K |
| Feb 9, 2026 | Vargeese Chandra | See Remarks | SELL | 3,228 | $13.45 | $43.4K |
| Feb 5, 2026 | BOLNO PAUL | President and CEO | A | 165,000 | $0.00 | $0.00 |
| Feb 5, 2026 | Vargeese Chandra | See Remarks | A | 45,625 | $0.00 | $0.00 |
| Feb 5, 2026 | Vargeese Chandra | See Remarks | A | 273,750 | $0.00 | $0.00 |
| Feb 5, 2026 | Francis Chris | See Remarks | A | 38,750 | $0.00 | $0.00 |
| Feb 5, 2026 | Francis Chris | See Remarks | A | 232,500 | $0.00 | $0.00 |
| Feb 5, 2026 | BOLNO PAUL | President and CEO | A | 1,000,000 | $0.00 | $0.00 |
| Feb 5, 2026 | Moran Kyle | Chief Financial Officer | A | 45,625 | $0.00 | $0.00 |
| Feb 5, 2026 | Moran Kyle | Chief Financial Officer | A | 273,750 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 5.7/10.
BULLISH
8-K
7/10
Wave Life Sciences reported Q1 2026 EPS of -$0.13, beating consensus estimates of -$0.34 by 61.8%, a
Apr 28, 2026
BULLISH
PRESS-RELEASE
7/10
Wave Life Sciences reported Q1 2026 revenue of $38.2M (vs consensus $7.9M) and EPS of -$0.13 (vs con
Apr 28, 2026
NEUTRAL
PRESS-RELEASE
4/10
Wave Life Sciences (WVE) announced it will report first-quarter 2026 financial results on April 28,
Apr 22, 2026
NEUTRAL
DEFA14A
4/10
Wave Life Sciences Ltd. (WVE) announced a plan to redomicile its parent company from Singapore to th
Apr 15, 2026
NEUTRAL
8-K
5/10
Wave Life Sciences is redomiciling from Singapore to Delaware, exchanging all Singapore shares for D
Apr 15, 2026
MIXED
8-K
7/10
Wave Life Sciences reported a significant year-over-year decline in revenue and a shift from net inc
Feb 26, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 20 analysts: 6 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$21.94 mean target
+279.5% upside
Strong Buy (1.13)
$12.00 Low
$43.00 High
| Metric | Value |
|---|---|
| Current Price | $5.78 |
| Target Low | $12.00 |
| Target Mean | $21.94 |
| Target Median | $18.50 |
| Target High | $43.00 |
| # Analysts | 16 |
| Recommendation | Strong Buy (1.13) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.30 | $-0.33 | $-0.25 | 2.7% | +0.0% | 6↑ 2↓ | $0.0B | -18.4% | 11 |
| Next Q 2026-09-30 |
$-0.31 | $-0.37 | $-0.27 | 1.6% | +0.0% | 7↑ 1↓ | $0.0B | -8.5% | 11 |
| Current FY 2026-12-31 |
$-0.88 | $-1.33 | $1.64 | 27.7% | +0.0% | 9↑ 0↓ | $0.1B | 34.0% | 12 |
| Next FY 2027-12-31 |
$-1.11 | $-1.78 | $-0.03 | -26.6% | +17.3% | 7↑ 3↓ | $0.1B | -10.0% | 12 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.302 | |
| 7d ago | $-0.302 | |
| 30d ago | $-0.302 | |
| 60d ago | $-0.326 | +0.024 |
| 90d ago | $-0.328 | +0.026 |
11 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 4, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Apr 30, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 29, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Apr 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Mar 25, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 12, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 5, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Feb 3, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Dec 15, 2025 | Truist Securities | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | Wedbush | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
53°
Neutral
Bearish
Neutral
Bullish
11 mentions
4 bullish
3 bearish
9 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 27, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| May 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 3, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 26, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| Mar 26, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
WVE DD
▲ 1
💬 0
⚡ 0.5
My Thesis On $WVE. RA Capital bought $54M after a 50% crash in this Ozempic Competitor.
▲ 1
💬 0
⚡ 0.5
WVE oversold?
▲ 1
💬 0
⚡ 0.5
WVE Results on 3-26-2026
▲ 1
💬 0
⚡ 0.5
Jun 3, 2026
Clinical Trial
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: WVE-006 (Phase 2)
Trial: A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
Sponsor: Wave Life Sciences
Jun 3, 2026
short_volume
Short Volume: WVE — 59.9% short (0.7M / 1.1M)
Short: 672,862 | Exempt: 324 | TRF Vol: 1,123,938 | Short Ratio: 59.9% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: WVE — 64.2% short (1.2M / 1.8M)
Short: 1,182,300 | Exempt: 4,673 | TRF Vol: 1,841,920 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
other
Wave Life Sciences to Present at Upcoming Investor Conferences
<p>CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlo
Jun 1, 2026
short_volume
Short Volume: WVE — 58.8% short (0.9M / 1.5M)
Short: 889,437 | Exempt: 251 | TRF Vol: 1,513,862 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: WVE — 55.7% short (0.6M / 1.1M)
Short: 603,238 | Exempt: 0 | TRF Vol: 1,082,662 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: WVE — 65.5% short (0.8M / 1.2M)
Short: 780,774 | Exempt: 0 | TRF Vol: 1,191,584 | Short Ratio: 65.5% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: WVE — 61.4% short (0.5M / 0.8M)
Short: 508,061 | Exempt: 5,701 | TRF Vol: 827,919 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
May 18, 2026
fda
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
<p><em>Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable o
May 15, 2026
short_volume
Short Volume: WVE — 58.1% short (1.0M / 1.7M)
Short: 969,563 | Exempt: 0 | TRF Vol: 1,669,934 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
other
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
<p>CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unloc
May 1, 2026
short_volume
Short Volume: WVE — 55.8% short (1.2M / 2.1M)
Short: 1,157,929 | Exempt: 374 | TRF Vol: 2,074,806 | Short Ratio: 55.8% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
earnings
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
<p><em>With recent FDA acceptance of the </em><em>Phase 2a </em><em>multidose portion </em><em>of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in ind
Apr 28, 2026
earnings_calendar
WVE Q1 2026 Earnings Scheduled — 2026-04-28
Apr 22, 2026
earnings
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
<p>CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unl